• Episode 200: Immune Checkpoint Inhibitors

  • Sep 2 2024
  • Length: Less than 1 minute
  • Podcast

Episode 200: Immune Checkpoint Inhibitors

Listen for free

View show details

  • Summary

  • We discuss a new class of medications, Immune Checkpoint Inhibitors, and their side effects.

    Hosts:
    Avir Mitra, MD
    Brian Gilberti, MD

    https://media.blubrry.com/coreem/content.blubrry.com/coreem/Immune_Checkpoint_Inhibitors.mp3 Download Leave a Comment Tags: Oncology Show Notes Overview of Immune Checkpoint Inhibitors (ICIs)
    • ICIs are a relatively new class of oncologic drugs that have revolutionized cancer treatment.
    • Unlike chemotherapy, ICIs help the immune system develop memory against cancer cells and adapt as the cancer mutates.
    • Since their release in 2011, ICIs have expanded to 83 indications for 17 different cancers, with approximately 230,000 patients using them.
    Mechanism of Action
    • Cancer cells can evade the immune system by binding to T cell receptors that downregulate the immune response.
    • ICIs work by blocking these receptors or ligands, preventing the downregulation and allowing T cells to proliferate and attack cancer cells.
    • Common ICIs
    Risks and Toxicities of ICIs
    • ICIs can lead to autoimmune attacks on healthy cells due to immune system upregulation.
    Show more Show less
Show more Show less

What listeners say about Episode 200: Immune Checkpoint Inhibitors

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available